Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)

HIV Clinical Trial

Official title:

Evaluation of Rapid Diagnostic Tests (RDT) in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases (NTD) in Patients Presenting With Persistent Fever (≥1 Week) in Cambodia, Nepal, Democratic Republic of the Congo and Sudan

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01766830
• Other study ID #: WP2-01-FEV
• Secondary ID: 260260
• Status: Completed
• Phase: N/A
• First received: January 9, 2013
• Last updated: October 26, 2016
• Start date: January 2013
• Est. completion date: July 2016

Study information

• Verified date: October 2016
• Source: University Hospital, Geneva
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Ethics CommitteeNepal: Health Research CouncilSudan: Ministry of HealthCongo, Democratic Republic of the: Ministry of HealthCambodia: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Tropical fevers have been a diagnostic challenge from the antiquity. Nowadays, despite the availability of good diagnostic capacities, undifferentiated febrile illnesses continue to be a thorny problem for travel physicians. In developing countries, the scarcity of skilled personnel and adequate laboratory facilities makes the differential diagnosis of fevers even more complex. Health care workers must often rely on syndrome-oriented empirical approaches to treatment and might overestimate or underestimate the likelihood of certain diseases. For instance Neglected Tropical Diseases (NTD) contribute substantially to the burden of persistent (more than 1 week) fevers in the Tropics, causing considerable mortality and major disability. These diseases are however rarely diagnosed at primary health care (PHC) level. The difficulty in establishing the cause of febrile illnesses has resulted in omission or delays in treatment, irrational prescriptions with polytherapy, increasing cost and development of drug resistance.

In resource-limited settings, clinical algorithms constitute a valuable aid to health workers, as they facilitate the therapeutic decision in the absence of good laboratory capacities. There is a critical lack of appropriate diagnostic tools to guide treatment of NTDs. While clinical algorithms have been developed for some NTDs, in most cases they remain empirical. Besides, they rarely take into account local prevalence data, do not adequately represent the spectrum of patients and differential diagnosis at the primary care level and often have not been properly validated. The purpose of the study is to develop evidence-based Rapid Diagnostic Test (RDT)-supported diagnostic guidelines for patients with persistent fever (≥ 1 week) in the Democratic Republic of the Congo (DRC), Sudan, Cambodia and Nepal.

Description:

This study is part of a large European Union (EU)-funded research project called NIDIAG that aims at developing integrated, evidence-based syndromic approach to improve management of NTD-related clinical syndromes. NIDIAG targets three non-specific clinical syndromes: the persistent fever, neurological, and intestinal syndrome. The objective of the project is to establish diagnostic guidelines for each of this syndrome, with a particular focus on severe and treatable neglected infectious diseases. The developed guidelines should integrate relevant Point-of-Care (POC)tests.

The persistent fever syndrome targeted by NIDIAG is defined as presence of fever for at least one week. The list of diseases - both NTD and other Infectious Diseases (ID) - that frequently cause persistent (≥1 week) fever in the study countries includes: Visceral Leishmaniasis (VL), Human Africa Trypanosomiasis (HAT), Enteric (typhoid, paratyphoid) fever, Malaria, Brucellosis, Melioidosis, Tuberculosis, Amoebic liver abscess, Relapsing fever, HIV, Rickettsial diseases, and Leptospirosis. The study will try to identify clinical and laboratory predictors of these diseases as well as validate existing RDTs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1927
• Est. completion date: July 2016
• Est. primary completion date: October 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 5 Years and older

Eligibility

Inclusion Criteria:

• fever for = 1 week

• = 5 years old (18 years onward in Cambodia)

Exclusion Criteria:

• unwilling or unable to give written informed consent

• unable in the study physician's opinion to comply with the study requirements

• existing laboratory confirmed diagnosis

• need of immediate intensive care due to shock or respiratory distress

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Amoebic Liver Abscess
• Brucellosis
• Enteric Fever
• Fever
• HIV
• Human African Trypanosomiasis
• Leishmaniasis
• Leishmaniasis, Visceral
• Leptospirosis
• Liver Abscess
• Malaria
• Melioidosis
• Relapsing Fever
• Rickettsia Infections
• Rickettsial Diseases
• Trypanosomiasis
• Trypanosomiasis, African
• Tuberculosis
• Typhoid Fever
• Visceral Leishmaniasis

Intervention

Device:
• rk28 ICT
rk28 ICT is an immunochromatographic assay intended for qualitative detection of IgG antibodies directed towards VL in human serum, plasma or whole blood. It is manufactured by EASE-Medtrend (Shanghai, China)
• IT LEISH (rK39)
IT LEISH is an immuno-chromatographic test, using the recombinant antigen K39, to detect the presence of antibodies against Leishmania spp. It is manufactured by BioRad laboratories, USA.
• Immunochromatographic HAT test
This is a lateral flow immunochromatographic test manufactured by Standard Diagnostics (Korea) in collaboration with FIND.
• HAT Serostrip
The HAT Serostrip is an immunochromatographic assay developed by Coris BioConcept, France, which is designed for remote field use in individual HAT suspects.
• Card Agglutination Trypanosoma Test (CATT)-10
The Card Agglutination Trypanosoma test (CATT) has been used for many years at large scale for mass screening of mostly asymptomatic individuals (CATT-R250). Unfortunately, its operating characteristics have only been evaluated in the context of patients with persistent fever. Although it is not strictly an RDT, the CATT is rather easily performed in remote settings, in particular since a new and more robust format (CATT-D10) allows to test a lower number of patients in peripheral health facilities. It is manufactured by the Institute of Tropical Medicine of Antwerp, Belgium.
• Typhidot M
The Typhidot M test is a dot enzyme immunoassay that detects IgM and IgG directed against Salmonella typhi. It is manufactured by Reszon Diagnostics International, Malaysia
• S. typhi IgM/IgG
The Salmonella typhi IgG/IgM Rapid Test is an immunochromatographic assay for the qualitative differential detection of IgG and IgM antibodies to Salmonella typhi in human serum, plasma or whole blood. It is manufactured by Standard Diagnostics (Korea)
• Test-it Typhoid IgM
Test-it Typhoid IgM lateral flow assay is a one-step immunochromatographic assay which uses a lipopolysaccharide (LPS) antigen derived from salmonella typhi for the detection of specific IgM antibodies. It is manufactured by Life Assay, South Africa.
• Test-it Leptospirosis IgM
The Test-it™ Leptospira lateral flow device detects IgM antibodies in humans against Leptospira in whole blood or serum. It is manufactured by Life Assay, South Africa
• Leptospira IgG/IgM
This test enables the differential detection of IgG and IgM antibodies to Leptospira interrogans. It is manufactured by Standard Diagnostics, Korea

Locations

Country	Name	City	State
Cambodia	Sihanouk Hospital Center of HOPE	Phnom Penh
Congo, The Democratic Republic of the	Institut National de Recherche Biomédicale	Kinshasa
Congo, The Democratic Republic of the	Reference Hospital Mosango and Kasay Health Centre	Mosango	Bandundu
Nepal	Dhankuta District hospital	Dhankuta	Koshi Zone
Nepal	BP Koirala Institute of Health Sciences	Dharan
Sudan	University of Khartoum	Khartoum
Sudan	Tabarak Allah Hospital	Tabarak Allah	Gedaref

Sponsors (6)

Lead Sponsor	Collaborator
University Hospital, Geneva	B.P. Koirala Institute of Health Sciences, Institut National de Recherche Biomédicale, Kinshasa, DRC, Institute of Tropical Medicine, Belgium, Sihanouk Hospital Center of HOPE, University of Khartoum

Countries where clinical trial is conducted

Cambodia,  Congo, The Democratic Republic of the,  Nepal,  Sudan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of Visceral Leishmaniasis (VL), Human African Trypanosomiasis (HAT) and other Neglected Tropical Diseases (NTDs)	Number of patients diagnosed with VL, HAT and other NTDs among those presenting with persistent(= 1 week) fever in one of the study sites	18 months	No
Primary	Identification of clinical and laboratory diagnostic indicators	Sensitivity, specificity, crude and adjusted likelihoods ratios (LR), and predictive values (post-test probabilities) of clinical and first-line laboratory predictors for the diagnosis of VL, HAT and other NTDs	18 months	No
Primary	Identification of reliable Rapid Diagnostic Tests (RDTs)	Assessment of sensitivity, likelihood ratios and performances (diagnostic accuracy) of the novel study RDTs for VL, HAT, enteric fever and	18 months	No
Primary	Predictive values of RDTs	Predictive values (post-test probabilities) of RDTs, alone and in combination, for the respective target conditions within the multi-disease approach	18 months	No
Secondary	Cost-effectiveness of the diagnostic tests	Unit costs of diagnostic tests for the diagnosis of HAT and other priority NTDs/IDs in the setting	18 months	No

External Links

•   NIDIAG Consortium website